Abstract
Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have